BPC-157 + TB-500 Stack
The most-researched soft-tissue recovery pairing — a gastric-derived cytoprotective peptide combined with an actin-binding regenerative peptide.
Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Why these two are stacked
BPC-157 and TB-500 act on different layers of the wound-healing cascade. BPC-157 upregulates the nitric oxide system, drives angiogenesis, and promotes GH-receptor expression in injured tissue. TB-500 (a synthetic fragment of thymosin beta-4) binds G-actin and drives cell migration, fibroblast recruitment, and re-epithelialization. The pair targets both blood-supply restoration and the cellular machinery needed to rebuild tissue.
Tissue repair is rate-limited by two things: getting blood to the injury (BPC-157's strength) and getting reparative cells to migrate into it (TB-500's strength). Combined, the pair is hypothesized to compress the inflammatory and proliferative phases of healing.
Researched together for
- •Tendon-to-bone and ligament healing (rodent)
- •Muscle tear and crush-injury models
- •Gastrointestinal mucosa repair (BPC-157)
- •Skin wound and burn healing (TB-500)
- •Reduction of fibrotic scar formation
Sample weekly schedule
| When | Research protocol |
|---|---|
| Loading · weeks 1–4 | BPC-157 daily + TB-500 2–3× per week. |
| Maintenance · weeks 5–8 | BPC-157 daily, TB-500 reduced to 1× per week. |
| Local vs systemic | BPC-157 is often dosed SC near the injury site; TB-500 is systemic by design. |
Timing notes
- •Splitting BPC-157 into AM + PM doses is common in tendon-injury research.
- •TB-500's multi-day half-life permits 2–3× weekly dosing.
- •Stacking is most measurable during the first 4–6 weeks of an injury.
Stack-specific considerations
- •Neither peptide is FDA-approved; both remain research-only in the U.S.
- •Most efficacy evidence is preclinical; human trials are limited.
- •Theoretical angiogenesis concerns: avoid with active malignancy.
- •Compounded TB-500 quality varies widely.
Frequently asked
Q.Why are BPC-157 and TB-500 so often researched together?
They hit complementary layers of healing — BPC-157 restores blood supply, while TB-500 drives the migration of fibroblasts and reparative cells.
Q.Can I inject BPC-157 directly into the injury site?
Research protocols frequently use subcutaneous administration close to the injured tissue. Intra-articular or intramuscular injections should only be done by a clinician.
Q.How long is a typical research cycle?
Most recovery protocols run 4–8 weeks. Longer cycles are studied for chronic tendinopathy, but on/off cycling is the norm.
Q.Does TB-500 work for old injuries?
Animal research suggests TB-500 can reactivate dormant repair in chronic injuries; human data is anecdotal.
Q.Is the combination safe with NSAIDs?
Preclinical work suggests BPC-157 may counteract NSAID-induced gastric damage, but the interaction has not been studied in humans. Most research subjects pause NSAIDs during the cycle.
Q.Will the stack reduce scar tissue?
Animal research shows reduced fibrosis with both peptides, particularly TB-500.
Q.Should I add GHK-Cu for skin and connective tissue?
Some research combines all three for chronic skin or wound applications. See our GHK-Cu + BPC-157 stack page for the rationale.